New risk markers for cardiovascular prevention

Area of Science:

• Cardiology
• Preventive Medicine
• Medical Risk Assessment

Background:

• Established cardiovascular (CV) risk models utilize classical factors like age, gender, smoking, blood pressure, and lipids.
• Accurate total CV risk estimation is vital before initiating management strategies in asymptomatic populations.
• Current models stratify individuals into low, moderate, high, and very high CV risk categories.

Purpose of the Study:

• To evaluate the predictive value of additional risk factors beyond classical ones for total CV risk estimation.
• To assess the impact of novel biomarkers and indicators of subclinical atherosclerotic disease on CV risk stratification.
• To determine the utility of incorporating these additional factors into existing CV risk models.

Main Methods:

• Review and analysis of existing cardiovascular risk models.
• Examination of the incremental predictive value of novel biomarkers.
• Assessment of the contribution of subclinical vascular damage indicators to risk stratification.
• Discussion on the potential re-classification of asymptomatic subjects based on new data.

Main Results:

• The contribution of novel biomarkers to total CV risk estimation is generally modest.
• Biomarker usage is most beneficial for subjects categorized at intermediate total CV risk.
• Detection of subclinical vascular damage can improve risk estimation for asymptomatic individuals near decision-making thresholds.
• Subclinical vascular damage offers a greater potential for re-classifying individuals into different risk categories.

Conclusions:

• Novel biomarkers have a limited but specific role in refining CV risk for intermediate-risk individuals.
• Detecting subclinical vascular damage is valuable for improving risk stratification in asymptomatic populations near critical thresholds.
• Further clinical trials are urgently needed to validate the utility of enhanced total CV risk estimation models in clinical practice.